Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy

Leukemia & Lymphoma
Samo RozmanBarbara Jezersek Novakovic

Abstract

Late-onset neutropenia (LON) following rituximab therapy is a recently recognized adverse effect occurring in various clinical settings. However, the true incidence and pathogenesis of this adverse effect are not fully understood. We retrospectively reviewed the medical records of 160 patients with diffuse large B-cell lymphoma (DLBCL) in complete remission (CR) following first-line treatment with rituximab-containing therapy. The incidence of LON was 26.9% (grade 1, 2, 3 and 4) and the incidence of severe LON (grade 3 and 4) was 7.5%. The risk factors for the occurrence of LON were not identified, and overall survival did not differ between patients who developed LON and those who did not. This study suggests that LON is a quite common complication to rituximab therapy. However, more studies are needed in order to elucidate the true mechanism behind and risk factors for LON.

References

Jun 8, 1999·The Journal of Experimental Medicine·P SchneiderJ Tschopp
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Mar 22, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BoyeA Engert
Mar 26, 2003·Seminars in Oncology·Peter Johnson, Martin Glennie
Jun 6, 2003·British Journal of Haematology·Kritika ChaiwatanatornFrank Firkin
Jun 27, 2003·The New England Journal of Medicine·Eric VoogPhilippe Solal-Céligny
Jul 15, 2006·Leukemia & Lymphoma·Peter McLaughlin
Oct 20, 2006·International Journal of Hematology·Kenji FukunoHisataka Moriwaki
Nov 3, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E NittaM Kurokawa
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Oct 6, 2007·The British Journal of Dermatology·R Rios-FernándezN Ortego-Centeno
Jan 12, 2008·Annual Review of Medicine·Arturo Molina
Apr 29, 2009·Leukemia & Lymphoma·Ron RamPia Raanani
May 6, 2009·American Journal of Hematology·Gillianne Geet Yi LaiRichard Quek
Feb 1, 2003·Seminars in Oncology·Peter Johnson, Martin Glennie

❮ Previous
Next ❯

Citations

Apr 17, 2015·Multiple Sclerosis and Related Disorders·Annika PlateTania Kümpfel
Aug 3, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Koichi KameiShuichi Ito
Sep 1, 2017·Expert Opinion on Drug Safety·Marta Pérez-De-LisManuel Ramos-Casals
Jan 9, 2021·Journal of Neurology·Clara Grazia ChisariFrancesco Patti

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.